Neratinib

• Description :

  Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively[1].

• Product Name Alternative :

  HKI-272

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  EGFR

• Type :

  Reference compound

• Related Pathways :

  JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Neratinib.html

• Purity :

  99.94

• Solubility :

  DMSO : 8.33 mg/mL (ultrasonic)

• Smiles :

  ClC1=C(OCC2=NC=CC=C2)C=CC(NC3=C(C#N)C=NC4=CC(OCC)=C(NC(/C=C/CN(C)C)=O)C=C43)=C1

• Molecular Formula :

  C30H29ClN6O3

• Molecular Weight :

  557.04

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Rabindran SK, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res, 2004, 64 (11), 3958-3965.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  EGFR/ErbB1/HER1; ErbB2/HER2

• CAS Number :

  [698387-09-6]